Biocon share news, announcements and annual reports
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Biocon Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2004
Last close ₹351.90up ₹1.20 (0.34%)BSE ₹352.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹350.70.
29 Oct: open ₹351.50, high ₹357.30, low ₹349.40
52-week range of traded prices to 29 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹57,349 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 115.79
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 64.11
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.69
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.14%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 31,13,378
Biocon share news and announcements
1,771 announcements, routine notices left out, newest first. Page 36 of 36.
Jul 2007
30 Jul · Business
Press release dated July 30, 2007, titled "Pharma - Biotech Alliance Neobiocon established in Dubiotech". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jul · Business
Press release dated July 19, 2007, titled "Abraxis Bioscience and Biocon Limited Announce Licensing Agreement for G-CSF in North America and the European Union". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Jul · Business
Press release dated July 18, 2007, titled "Biocon to Focus on Biopharmaceuticals, Divesting Enzymes for USD 115 Million to Novozymes". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Jul · Business
Press release dated July 18, 2007, titled "Biocon's Q1 FY'08 Delivers 36% Profit Growth". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 22740 lacs for quarter ending on 30-JUN-2007 against Rs. 18370 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 4486 lacs for the quarter ending on 30-JUN-2007 against Rs. 2757 lacs for the quarter ending on 30-JUN-2006.18 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 27083 lacs for quarter ending on 30-JUN-2007 against Rs. 21151 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 5283 lacs for the quarter ending on 30-JUN-2007 against Rs. 3891 lacs for the quarter ending on 30-JUN-2006.
Jun 2007
25 Jun · Board meeting
Inter alia, to approve / take on record the audited financial results of the Company for the quarter ended on June 30, 2007.7 Jun · Business
Press release dated June 07, 2007, titled "Biocon signs Memorandum of Understanding with Deakin University , Australia - To establish Deakin Research Institute in Bangalore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
31 May · Business
Press release dated May 31, 2007, titled "Biocon Limited and Students Working Against Tobacco (SWAT) conduct unique campaign on World Anti-Tobacco Day". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 May · Meeting
Annual General Meeting of the Company will be held on July 18, 2007.
Apr 2007
19 Apr · Dividend
Board, at its meeting held on April 19, 2007, has recommended a dividend for the year (subject to the approval of shareholders at the ensuing Annual General Meeting) of Rs. 3 per Equity Share of Rs. 5 each (60%). Further, the register of members and share transfer books will remain closed from July 02, 2007 to July 19, 2007 both days inclusive, for the purpose of payment of dividend.19 Apr · Business
Press release dated April 19, 2007, titled "Biocon's FY 2006-07 performance shows healthy growth - Revenues Rs. 990 crs; EBITDA Rs. 287 crs; PAT Rs. 200 crs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Apr · Board meeting
Inter-alia to approve / take on record the audited financial results of the Company for the year ended on 31st March, 2007 and to consider recommendation of payment of dividend, if any, for the year 2006-2007.
Mar 2007
21 Mar · Business
Press release dated March 21, 2007, titled "Biocon conducts ground breaking ceremony of new research facility at Biocon Park". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Mar · Business
Press release, dated March 14, 2007, titled "Biocon's Syngene enters into Research Partnership with Bristol-Myers Squibb." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Mar · Business
Press release dated March 08, 2007, titled "Biocon Limited Unveils A Comprehensive Portfolio of Renal Therapy Products". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2007
20 Feb · Business
Press release dated February 20, 2007, titled "Biocon and Bentley Announce Approval and Expansion of Bentley's Nasulin(TM) Phase II Studies in India". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Feb · Miscellaneous
Biocon Limited is contemplating to acquire about 50 acres of land in Jawaharlal Nehru Pharma City in Vishakapatna for its future manufacturing expansion needs. The proposed investment is in the order of Rs. 500 crores over five years
Jan 2007
18 Jan · Business
Two press releases dated January 18, 2007, titled "Bicon's 9 Months FY 07 Delivers Robust Profits, Revenues Rs. 710 crs : EBITDA Rs. 200 crs : PAT Rs. 140 crs" and "Biocon Grants Exclusive Marketing License for BIOMAb EGFR for Pakistan". The details of the press releases shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Jan · Business
Press release dated January 05, 2007, titled "Biocon Limited and Neopharma sign MOU for a JV". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jan · Board meeting
Inter alia, to approve / take on record the audited financial results of the Company for the quarter ending on 31st December, 2006.